Hildegard Keppeler

2.1k total citations
43 papers, 1.7k citations indexed

About

Hildegard Keppeler is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Hildegard Keppeler has authored 43 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Immunology, 16 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in Hildegard Keppeler's work include Immune Cell Function and Interaction (9 papers), Phagocytosis and Immune Regulation (9 papers) and CAR-T cell therapy research (6 papers). Hildegard Keppeler is often cited by papers focused on Immune Cell Function and Interaction (9 papers), Phagocytosis and Immune Regulation (9 papers) and CAR-T cell therapy research (6 papers). Hildegard Keppeler collaborates with scholars based in Germany, United States and Switzerland. Hildegard Keppeler's co-authors include Kirsten Lauber, Sebastian Wesselborg, Frank Lammert, Martin Herrmann, Antje S Löffler, Sebastian Alers, Björn Stork, Alexandra Dieterle, David G. Campbell and Hermann E. Wasmuth and has published in prestigious journals such as Journal of Biological Chemistry, Nature Genetics and Blood.

In The Last Decade

Hildegard Keppeler

42 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hildegard Keppeler Germany 19 671 531 522 327 277 43 1.7k
Pia Rantakari Finland 22 565 0.8× 294 0.6× 540 1.0× 159 0.5× 283 1.0× 46 1.5k
Ming‐Xiao He United States 16 929 1.4× 511 1.0× 217 0.4× 351 1.1× 398 1.4× 24 2.0k
Peter Hasselblatt Germany 24 463 0.7× 325 0.6× 380 0.7× 173 0.5× 139 0.5× 46 1.5k
Tsuyoshi Iwasaki Japan 24 597 0.9× 167 0.3× 538 1.0× 178 0.5× 207 0.7× 81 1.6k
Shishir Shetty United Kingdom 21 566 0.8× 723 1.4× 799 1.5× 269 0.8× 483 1.7× 81 2.4k
Deanna Sverdlov United States 15 491 0.7× 675 1.3× 226 0.4× 321 1.0× 175 0.6× 23 1.6k
Toshikazu Gondo Japan 27 732 1.1× 384 0.7× 181 0.3× 411 1.3× 350 1.3× 98 2.0k
Judith Agudo United States 28 718 1.1× 300 0.6× 645 1.2× 368 1.1× 474 1.7× 48 2.1k
Dirk J. van der Windt United States 25 569 0.8× 474 0.9× 649 1.2× 1.6k 4.9× 189 0.7× 52 2.8k
Maya Gulubova Bulgaria 21 450 0.7× 205 0.4× 499 1.0× 233 0.7× 500 1.8× 107 1.5k

Countries citing papers authored by Hildegard Keppeler

Since Specialization
Citations

This map shows the geographic impact of Hildegard Keppeler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hildegard Keppeler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hildegard Keppeler more than expected).

Fields of papers citing papers by Hildegard Keppeler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hildegard Keppeler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hildegard Keppeler. The network helps show where Hildegard Keppeler may publish in the future.

Co-authorship network of co-authors of Hildegard Keppeler

This figure shows the co-authorship network connecting the top 25 collaborators of Hildegard Keppeler. A scholar is included among the top collaborators of Hildegard Keppeler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hildegard Keppeler. Hildegard Keppeler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Keppeler, Hildegard, Rahel Fitzel, Claudia Lengerke, et al.. (2024). Treatment response of advanced HNSCC towards immune checkpoint inhibition is associated with an activated effector memory T cell phenotype. Frontiers in Oncology. 14. 1333640–1333640. 1 indexed citations
2.
Schairer, Rebekka, et al.. (2024). CD19-chimeric antigen receptor-invariant natural killer T cells transactivate NK cells and reduce alloreactivity. Cytotherapy. 27(1). 7–15. 2 indexed citations
3.
Schairer, Rebekka, Hildegard Keppeler, Hannes Schmid, et al.. (2024). PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity. Journal for ImmunoTherapy of Cancer. 12(1). e007829–e007829. 7 indexed citations
4.
Keppeler, Hildegard, et al.. (2023). Uncovering NOTCH1 as a Promising Target in the Treatment of MLL-Rearranged Leukemia. International Journal of Molecular Sciences. 24(19). 14466–14466. 1 indexed citations
5.
Hentrich, Thomas, Rebekka Schairer, Hildegard Keppeler, et al.. (2023). The RORɣ/SREBP2 pathway is a master regulator of cholesterol metabolism and serves as potential therapeutic target in t(4;11) leukemia. Oncogene. 43(4). 281–293. 7 indexed citations
6.
Schneidawind, Dominik, Susanne S. Renner, Daniel Atar, et al.. (2022). Low Graft Invariant Natural Killer T-Cell Dose Is a Risk Factor for Cytomegalovirus Reactivation After Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 28(8). 513.e1–513.e4. 4 indexed citations
7.
Schmid, Hannes, Hildegard Keppeler, Klaus Schulze‐Osthoff, et al.. (2021). Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells. Haematologica. 107(2). 427–436. 14 indexed citations
8.
Einhaus, Jakob, Ann‐Christin Pecher, Hannes Schmid, et al.. (2020). Inhibition of effector B cells by ibrutinib in systemic sclerosis. Arthritis Research & Therapy. 22(1). 66–66. 34 indexed citations
9.
Keppeler, Hildegard, Hannes Schmid, Dominik Schneidawind, et al.. (2019). Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9. Oncogene. 38(46). 7181–7195. 26 indexed citations
10.
Wolf, Benita, Christine S. Falk, Kai Breuhahn, et al.. (2016). Inducing Differentiation of Premalignant Hepatic Cells as a Novel Therapeutic Strategy in Hepatocarcinoma. Cancer Research. 76(18). 5550–5561. 13 indexed citations
11.
Dieterle, Alexandra, Philip Böhler, Hildegard Keppeler, et al.. (2013). PDK1 controls upstream PI3K expression and PIP3 generation. Oncogene. 33(23). 3043–3053. 38 indexed citations
12.
Harre, Ulrike, Hildegard Keppeler, Natacha Ipseiz, et al.. (2012). Moonlighting osteoclasts as undertakers of apoptotic cells. Autoimmunity. 45(8). 612–619. 50 indexed citations
13.
Soeroes, Szabolcs, Michaela Waibel, Hildegard Keppeler, et al.. (2009). Cell Surface Externalization of Annexin A1 as a Failsafe Mechanism Preventing Inflammatory Responses during Secondary Necrosis. The Journal of Immunology. 183(12). 8138–8147. 65 indexed citations
14.
Wasmuth, Hermann E., Frank Lammert, Mirko Moreno Zaldivar, et al.. (2009). Antifibrotic Effects of CXCL9 and Its Receptor CXCR3 in Livers of Mice and Humans. Gastroenterology. 137(1). 309–319.e3. 130 indexed citations
15.
16.
Berg, Christoph P., Gerburg M. Stein, Hildegard Keppeler, et al.. (2007). Apoptosis-associated antigens recognized by autoantibodies in patients with the autoimmune liver disease primary biliary cirrhosis. APOPTOSIS. 13(1). 63–75. 18 indexed citations
17.
Wasmuth, H., Anna Glantz, Hildegard Keppeler, et al.. (2006). Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene. Gut. 56(2). 265–270. 114 indexed citations
18.
Wasmuth, Hermann E., Hildegard Keppeler, Ulrike Herrmann, et al.. (2006). Coinheritance of Gilbert syndrome–associated UGT1A1 mutation increases gallstone risk in cystic fibrosis†. Hepatology. 43(4). 738–741. 44 indexed citations
19.
Hillebrandt, Sonja, Hermann E. Wasmuth, Ralf Weiskirchen, et al.. (2005). Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nature Genetics. 37(8). 835–843. 208 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pia Rantakari Breakdown of academic impact, for papers by Ming‐Xiao He Breakdown of academic impact, for papers by Peter Hasselblatt Breakdown of academic impact, for papers by Tsuyoshi Iwasaki Breakdown of academic impact, for papers by Shishir Shetty Breakdown of academic impact, for papers by Deanna Sverdlov Breakdown of academic impact, for papers by Toshikazu Gondo Breakdown of academic impact, for papers by Judith Agudo Breakdown of academic impact, for papers by Dirk J. van der Windt Breakdown of academic impact, for papers by Maya Gulubova
Rankless by CCL
2026